Genomic analysis of prostate cancer has not answered key clinical questions such as "Which tumors are likely to recur?" or "Which pathways should we target for treatment?" The study by Taylor et al., initiated by the late William Gerald, published in this issue of Cancer Cell is a game changer.
Copyright (c) 2010 Elsevier Inc. All rights reserved.